# Oral Anticoagulation in Hemodialysis

> **NCT03799822** · PHASE4 · COMPLETED · sponsor: **Onze Lieve Vrouw Hospital** · enrollment: 132 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban 10 MG Oral Tablet
- **DIETARY_SUPPLEMENT:** MK-7 2000µg thrice weekly
- **DRUG:** Vitamin K Antagonist - Drug

## Key facts

- **NCT ID:** NCT03799822
- **Lead sponsor:** Onze Lieve Vrouw Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2020-09-15
- **Final completion:** 2020-10-01
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2020-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03799822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03799822, "Oral Anticoagulation in Hemodialysis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03799822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*